Company profile: Cyclerion Therapeutics
1.1 - Company Overview
Company description
- Provider of soluble guanylate cyclase (sGC) pharmacology-based therapeutics, including praliciguat, an oral systemic sGC stimulator licensed to Akebia for rare kidney disease; olinciguat, an oral vascular sGC stimulator for cardiovascular diseases; and CNS-directed sGC stimulators zagociguat and CY3018 sold to Tisento, showing brain effects on blood flow, connectivity, cognition.
Products and services
- Olinciguat: Clinical-stage vascular sGC stimulator intended for cardiovascular diseases, affecting vascular function, inflammation, and fibrosis in preclinical models, demonstrating targeted modulation of vascular pathophysiology
- Praliciguat: Systemic sGC stimulator for rare kidney disease, with demonstrated distribution to adipose, kidney, heart, and liver tissues, indicating broad tissue exposure and pharmacologic reach
- Zagociguat: CNS-penetrant sGC stimulator showing improvements in cerebral blood flow, brain connectivity, and cognitive performance in clinical studies, highlighting CNS activity relevant to neurological indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cyclerion Therapeutics
Soleno Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies, developing DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral treatment in development for Prader-Willi syndrome (PWS) and other rare endocrine disorders, designed to reduce hyperphagia, improve behavior, and manage metabolic health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Soleno Therapeutics company profile →
Lumos Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical programs developing a novel treatment for Creatine Transporter Deficiency and LUM-201 for Pediatric Growth Hormone Deficiency, an oral small molecule that stimulates growth hormone secretion from the pituitary; supporting the OraGrowtH210 Phase 2 and OraGrowtH212 PK/PD studies, a Predictive Enrichment Markers strategy to identify responders, and an Expanded Access/Compassionate Use program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumos Pharma company profile →
Pharming
HQ: The Netherlands
Website
- Description: Provider of protein replacement therapies and precision medicines, including Joenja (leniolisib), an oral, selective PI3Kδ inhibitor approved to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharming company profile →
Aro Biotherapeutics
HQ: United States
Website
- Description: Provider of tissue-targeted genetic medicines leveraging Centyrins, a proprietary small engineered protein platform, for targeted delivery to specific cells. Develops oligonucleotide-based therapeutics that modulate gene expression, including ABX1100, a Centyrin-siRNA conjugate targeting CD71 and Gys1 mRNA for Pompe disease to reduce muscle glycogen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aro Biotherapeutics company profile →
Manchester Pharma
HQ: United States
Website
- Description: Provider of specialty pharmaceutical capabilities focused on the identification, development, FDA approval, and commercialization of new therapeutic modalities to address the special needs of patients with ultra-rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Manchester Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cyclerion Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cyclerion Therapeutics
2.2 - Growth funds investing in similar companies to Cyclerion Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cyclerion Therapeutics
4.2 - Public trading comparable groups for Cyclerion Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →